 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Research Articles |
OBJECTIVE: To evaluate the role of budesonide inhalation suspension (BIS) in the treatment of children with asthma. DATA SOURCES: Literature identified through Medline (1966-November 2000) and references obtained from selected articles. Search terms included budesonide and asthma. DATA SYNTHESIS: Asthma is a chronic inflammatory disease that affects approximately 4.8 million children in the US. By reducing inflammation, corticosteroids decrease symptoms and improve lung function. As the first nebulized corticosteroid, BIS offers an important treatment option for children with persistent asthma. CONCLUSIONS: BIS is effective in reducing symptoms and improving lung function in children with asthma. It should be used in children ages 1-8 years with moderate to severe persistent asthma who are unable to effectively use a metered-dose inhaler with or without a spacer or a dry-powder inhaler.
This article has been cited by other articles:
|
|
 |
|
  S. M Gawchik Successful Treatment of Previously Uncontrolled Adult Asthma with Budesonide Inhalation Suspension: Five-Year Case Histories Ann. Pharmacother., October 1, 2007; 41(10): 1728 - 1733. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
